APR January/February 2022 - 67

« FORMULATION AND DEVELOPMENT
Figure 6. Third Party Collaboration
integration with MS365 demonstrated the potential to speed the
movement of molecule information from Research to Development
(scale-up) and ultimately to manufacturing.
Related to this, but with its own unique nuances, is the transfer and
sharing of molecule-based information with third party organizations.
Over roughly the past decade the pharmaceutical industry has shifted
a high percentage of its rule-based testing and an increasing amount
of judgement-based work to contract research organizations (CROs).
Scientists have struggled to effectively collaborate with CRO based
scientists for activities like troubleshooting, method development,
problem solving and knowledge transfer.
In the POC, Eli Lilly leveraged Iota to neatly organize and " package " this
information for technical transfer internally (Figure 6). It would appear
to our participants that this same capability could be leveraged with
CROs in a similar fashion and allow for real-time collaboration. The key
to this is the nearly ubiquitous use of RealWear MS365 applications
across companies. Microsoft Excel has long been the desktop tool
of choice for " discrete " numeric results and analysis. Cloud-based
storage now allows, with security controls in place, authenticated
users from anywhere in our partner network to access and contribute
to this content. Additional tools like Teams, PowerApps and Power
Automate allow citizen developers or solution providers to organize
this information in a way that makes sense to our uniquely technical
audiences.
Iota demonstrated the
ability
to interface multiple
partner organizations, maintain needed confidentiality and firewalls
and develop apps, workflows and dashboards that enhanced the
information workflow (Figure 7).
CROs also will find their burden eased by the use of this design.
Many CROs have limitations on staff and budgets that increase the
importance of being efficient. Again, with the ubiquity of MS365 many
CROs should not require additional software support, installation or
licensing to realize a positive impact. This allows both large and small
organizations to bring their unique capabilities to bear in the pursuit
of developing innovative health outcomes.
Eli Lilly found that the use of head mounted wearable devices from
RealWear combined with the use of Varya's Iota platform greatly
eased the transfer of technical information within the organization.
Specifically, this meant significantly reduced technical transfers
between Product Development organizations and Manufacturing.
Similarly, the team identified significant opportunities to streamline
our work with CROs, given the ease of which collaboration partners
could share notes, results and methods. The combination of these
improvements allowed our scientists to create multi-user, collaborative
'notebooks' where information could be expanded to include video,
image and audio content and information could be exchanged
internally and externally easily and securely.
www.americanpharmaceuticalreview.com |
| 67
»
http://www.americanpharmaceuticalreview.com

APR January/February 2022

Table of Contents for the Digital Edition of APR January/February 2022

APR January/February 2022 - Cover1
APR January/February 2022 - Cover2
APR January/February 2022 - 1
APR January/February 2022 - 2
APR January/February 2022 - 3
APR January/February 2022 - 4
APR January/February 2022 - 5
APR January/February 2022 - 6
APR January/February 2022 - 7
APR January/February 2022 - 8
APR January/February 2022 - 9
APR January/February 2022 - 10
APR January/February 2022 - 11
APR January/February 2022 - 12
APR January/February 2022 - 13
APR January/February 2022 - 14
APR January/February 2022 - 15
APR January/February 2022 - 16
APR January/February 2022 - 17
APR January/February 2022 - 18
APR January/February 2022 - 19
APR January/February 2022 - 20
APR January/February 2022 - 21
APR January/February 2022 - 22
APR January/February 2022 - 23
APR January/February 2022 - 24
APR January/February 2022 - 25
APR January/February 2022 - 26
APR January/February 2022 - 27
APR January/February 2022 - 28
APR January/February 2022 - 29
APR January/February 2022 - 30
APR January/February 2022 - 31
APR January/February 2022 - 32
APR January/February 2022 - 33
APR January/February 2022 - 34
APR January/February 2022 - 35
APR January/February 2022 - 36
APR January/February 2022 - 37
APR January/February 2022 - 38
APR January/February 2022 - 39
APR January/February 2022 - 40
APR January/February 2022 - 41
APR January/February 2022 - 42
APR January/February 2022 - 43
APR January/February 2022 - 44
APR January/February 2022 - 45
APR January/February 2022 - 46
APR January/February 2022 - 47
APR January/February 2022 - 48
APR January/February 2022 - 49
APR January/February 2022 - 50
APR January/February 2022 - 51
APR January/February 2022 - 52
APR January/February 2022 - 53
APR January/February 2022 - 54
APR January/February 2022 - 55
APR January/February 2022 - 56
APR January/February 2022 - 57
APR January/February 2022 - 58
APR January/February 2022 - 59
APR January/February 2022 - 60
APR January/February 2022 - 61
APR January/February 2022 - 62
APR January/February 2022 - 63
APR January/February 2022 - 64
APR January/February 2022 - 65
APR January/February 2022 - 66
APR January/February 2022 - 67
APR January/February 2022 - 68
APR January/February 2022 - 69
APR January/February 2022 - 70
APR January/February 2022 - 71
APR January/February 2022 - 72
APR January/February 2022 - 73
APR January/February 2022 - 74
APR January/February 2022 - 75
APR January/February 2022 - 76
APR January/February 2022 - 77
APR January/February 2022 - 78
APR January/February 2022 - 79
APR January/February 2022 - 80
APR January/February 2022 - 81
APR January/February 2022 - 82
APR January/February 2022 - 83
APR January/February 2022 - 84
APR January/February 2022 - Cover3
APR January/February 2022 - Cover4
https://www.nxtbookmedia.com